Journal
JOURNAL OF HEPATOLOGY
Volume 54, Issue 3, Pages 449-454Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2010.07.046
Keywords
Peginterferon; Entecavir; Hepatitis B; Quantitative HBsAg
Categories
Funding
- Foundation for Liver Research (SLO), Rotterdam, The Netherlands
- SLO
- Schering-Plough International (Kenilworth, NJ)
- F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
- Bristol Myers Squibb
- Gilead Sciences
- Novartis
- Roche
- Schering-Plough
Ask authors/readers for more resources
Background & Aims: We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B virus (HBV) infection during peginterferon (PEG-IFN) and entecavir (ETV) monotherapy. Methods: HBsAg was quantified (Abbott ARCHITECT) at baseline and during antiviral therapy (weeks 12, 24, 36, 48) in hepatitis B e antigen (HBeAg-) positive patients treated with ETV (n = 33) or PEG-IFN (n = 61) and in HBeAg-negative patients treated with ETV (n = 37) or PEG-IFN (n = 69). Results: Within the HBeAg-positive population, patients treated with PEG-IFN tended to have a steeper HBsAg decline than ETV-treated patients (mean decline 0.94 versus 0.38 log IU/ml at week 48, p = 0.07 for comparison of the slope of HBsAg decline). The HBsAg decline was larger in those patients who became HBeAg negative, irrespective of the treatment regimen. A decline in HBsAg was confined to ETV-treated patients with elevated baseline alanine aminotransferase (ALT) levels, whereas HBsAg decline was not associated with baseline ALT in patients treated with PEG-IFN. Within the HBeAg-negative population, PEG-IFN induced a significant HBsAg decline, while HBsAg did not decrease in ETV-treated patients (0.56 versus -0.10 log IU/ml, p <0.001). Both in HBeAg-positive and HBeAg-negative patients, the decline in serum HBV DNA was larger in patients who received ETV as compared to patients treated with PEG-IFN. Conclusions: In HBeAg-positive patients, the decline in serum HBsAg is mainly confined to patients who clear HBeAg, by either PEG-IFN or ETV treatment. In HBeAg-negative patients, PEG-IFN therapy resulted in a significant reduction in HBsAg levels, whereas HBsAg did not decrease in ETV-treated patients. (c) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available